Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Company

Johnson & Johnson

Pharmaceutical intelligence for Johnson & Johnson with 7 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals
2
Catalysts
5
Assets
3

Recent signals(2)

RegulatoryJuly 28, 2026

Johnson & Johnson Initiates 5-Year Safety Study for Mentor Breast Implants in China

Johnson & Johnson is conducting a 5-year observational study to evaluate the long-term safety of Mentor breast implants in the Chinese population.

ClinicalJuly 26, 2026

Johnson & Johnson's Varipulse Catheter Study Targets Paroxysmal Atrial Fibrillation

A clinical trial is underway to evaluate the long-term effectiveness of the Varipulse Catheter in patients with paroxysmal atrial fibrillation under optimized sedation.

Upcoming catalysts(1)

PDUFA Date

Johnson & Johnson — Caplyta

MDD approval would significantly expand Caplyta commercial footprint.

August 5, 2026 · NDA/BLA

Regulatory activity

(1)
RegulatoryJuly 28, 2026

Johnson & Johnson Initiates 5-Year Safety Study for Mentor Breast Implants in China

Johnson & Johnson is conducting a 5-year observational study to evaluate the long-term safety of Mentor breast implants in the Chinese population.

Clinical activity(1)

ClinicalJuly 26, 2026

Johnson & Johnson's Varipulse Catheter Study Targets Paroxysmal Atrial Fibrillation

A clinical trial is underway to evaluate the long-term effectiveness of the Varipulse Catheter in patients with paroxysmal atrial fibrillation under optimized sedation.

Competitive activity

No signals indexed for this entity yet.

Assets

Caplyta →
Johnson →
Stelara →

Therapeutic areas

Atrial Fibrillation →
Cardiology →
Gastroenterology · Inflammatory Bowel Disease →
Immunology · IL-12/23 →
Immunology · IL-12/23 Inhibitor →
Immunology · Psoriasis and Autoimmune Diseases →
Medical Devices →
Neuropsychiatry →
Surgery →

Indications

Major depressive disorder →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.